The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation.

ABSTRACT:

Introduction

Biomarkers play a crucial role in understanding Alzheimer's disease (AD) pathogenesis and treatment effects. However, comparing biomarker measures without standardization and appreciating their magnitude relative to the disease can be challenging.

Methods

To address this issue, we propose the CentiMarker approach, similar to Centiloid, which provides a standardized scale between normal (0) and nearly maximum abnormal AD (100) ranges. We applied this scale to cerebrospinal fluid (CSF) biomarkers in dominantly inherited AD and sporadic AD cohorts.

Results

CentiMarkers facilitated the interpretation of disease abnormality, demonstrating comparable changes and distributions of AD biomarkers across disease stages. CentiMarkers make the treatment effect more co

SUBMITTER: Wang G 

PROVIDER: S-EPMC12000244 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature